Fibrocell Science, Inc. , a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that it has entered into a securities purchase agreement with certain of its existing investors for the sale of $8.0 million of the Company’s Series A Convertible Preferred Stock and accompanying common stock warrants . Fibrocell has agreed to sell an aggregate of 8,000 units for a purchase price of $1,000 per Unit, with each Unit consisting of one share of Preferred Stock with an initial stated value of $1,000 convertible into shares of the Company’s common stock at a conversion price of $0.7757, and Warrants to purchase 10,313,263 shares of Common Stock .